We used the Nucleic Acid Linked Immuno‐Sandwich Assay (NULISA) central nervous system panel for biomarker quantification in plasma, serum, and cerebrospinal fluid of patients with AD, mild cognitive impairment, Lewy body dementia, progranulin (GRN) mutation carriers. The gene discussed is GRN; the disease is Alzheimer disease.